Recently, a robust CRISPR/Cas9 target gene activation (TGA) technology promoted in vivo trans-differentiation of liver cells into insulin-producing cells and ameliorated hyperglycemia by increasing serum insulin levels in STZ-treated diabetic mice (38). This evidence concerns the gene INS and Hyperglycemia.